• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Genprex Inc.

    6/26/26 4:46:21 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    S-8 1 gnpx20260526_s8.htm FORM S-8 gnpx20260526_s8.htm

     

    As filed with the Securities and Exchange Commission on June 26, 2026

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    GENPREX, INC.

    (Exact name of registrant as specified in its charter)

     

       

    Delaware

     

    90-0772347

     

     

       

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification Number)

     

     

     

     

     

     

    3300 Bee Cave Road #650-227

    Austin, Texas

      78746

     

     
     

     

    (Address of Principal Executive Offices)

      (Zip Code)

     

     

     

     

     

    Genprex, Inc. 2018 Equity Incentive Plan (As Amended and Restated Effective April 15, 2026)

     

     
     

     

    (Full title of the plan)

     

     

     

     

     

    Ryan M. Confer

    President, Chief Executive Officer, and Chief Financial Officer

    3300 Bee Cave Road #650-227

    Austin, TX 78746

     

     
     

     

    (Name and address of agent for service)

     

     

     

     

     

    (877) 774-4679

     

     
     

     

    (Telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Kate Basmagian, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, Genprex, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering 1,850,000 additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), issuable under the Registrant’s 2018 Equity Incentive Plan (As Amended and Restated Effective April 15, 2026) (the “Amended 2018 Plan”) following the approval of the Amended 2018 Plan by the Registrant’s stockholders at its annual meeting held on June 18, 2026.

     

    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 of the Registrant filed with the Commission on April 2, 2020 (Registration No. 333-237543), on August 16, 2022 (Registration No. 333-266896), on February 17, 2023 (Registration No. 333-269865), on April 17, 2024 (Registration No. 333-278758), on January 24, 2025 (Registration No. 333-284492), on November 14, 2025 (Registration No. 333-291548), and on January 9, 2026 (Registration No. 333-292654), including any amendments thereto or filings incorporated therein, are incorporated herein by this reference to the extent not replaced or changed hereby.  To the extent any such Registration Statements on Form S-8 were filed prior to the effectiveness of the Registrant’s reverse stock split(s) with shares stated therein on a pre-split basis, the shares of Common Stock registered by the foregoing Registration Statements on Form S-8 have been automatically adjusted to give effect to, in each case as appropriate, (i) the Registrant’s 1-for-50 reverse stock split of the issued and outstanding shares of Common Stock effective as of 12:01 Eastern Time on October 21, 2025 and (ii) the Registrant’s 1-for-40 reverse stock split of the issued and outstanding shares of Common Stock effective as of 12:01 Eastern Time on February 2, 2024.

     

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement. 

     

    1

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Commission pursuant to the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

     

    ●

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026;

         
      ● The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the Commission on May 13, 2026; 
         
     

    ●

    The Registrant’s Current Reports on Form 8-K filed with the Commission on January 6, 2026, January 7, 2026, January 9, 2026, February 10, 2026, February 23, 2026, March 18, 2026, April 21, 2026, April 28, 2026, April 30, 2026, May 14, 2026, May 26, 2026, June 12, 2026, June 18, 2026 and June 22, 2026 (other than any portions thereof deemed furnished and not filed); 

         
      ● The Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 29, 2026; and 
         
     

    ●

    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on October 13, 2017, as updated by the Description of Registrant’s Securities set forth on Exhibit 4.24 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026, and any amendments thereto or reports filed for the purposes of updating such description.

     

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

    II-1

     

     

    Item 8.

    Exhibits

     

    Exhibit

    Number

     

    Description of Exhibit

         
    3.1   Amended and Restated Certificate of Incorporation of the Registrant, dated April 3, 2018, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on April 10, 2018.
         
    3.2   Certificate of Amendment of the Amended and Restated Certificate of Incorporation, dated January 31, 2024, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on January 31, 2024.
         
    3.3   Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Genprex, Inc., dated October 16, 2025, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed on October 17, 2025.
         
    3.4   Amended and Restated Bylaws of the Registrant, dated April 3, 2018, incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K filed on April 10, 2018.
         
    3.5   Amendment No. 1 to the Amended and Restated Bylaws of the Registrant, adopted and approved by the Registrant’s Board of Directors on October 18, 2023, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on October 23, 2023.
         
    3.6   Amendment No. 2 to the Amended and Restated Bylaws of the Registrant, adopted and approved by Registrant’s Board of Directors on March 29, 2025, incorporated by reference to Exhibit 3.5 of the Registrant’s Annual Report on Form 10-K filed on April 1, 2025.
         
    4.1   Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017).

     

     

     

    5.1*

     

    Opinion of Lowenstein Sandler LLP.

         
    10.1   Genprex, Inc. 2018 Equity Incentive Plan (As Amended and Restated Effective April 15, 2026), incorporated by reference to Appendix A of the Registrant’s Proxy Statement filed on April 29, 2026.
         
    10.2   Form of Notice of Stock Option Grant and Stock Option Agreement, incorporated by reference to Exhibit 10.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on April 1, 2024.
         
    10.3   Form of Notice of Restricted Stock Award and Restricted Stock Agreement, incorporated by reference to Exhibit 10.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on April 1, 2024.
         
    10.4   Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement, incorporated by reference to Exhibit 10.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on April 1, 2024.
         
    10.5   Form of Employee Stock Option Grant Notice and Option Agreement, incorporated by reference to Exhibit 10.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on April 1, 2024.

     

     

     

    23.1*   Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm.
         

    23.2*

     

    Consent of Lowenstein Sandler LLP (included in Exhibit 5.1).

         

    24.1*

     

    Power of Attorney (included on the signature page to this Registration Statement on Form S-8).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on June 26, 2026.

     

     

    GENPREX, INC.

     

     

    By:  /s/ Ryan M. Confer

    Name:  Ryan M. Confer

    Title:    President, Chief Executive Officer and Chief Financial Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan Confer as his true and lawful attorney-in-fact and agent with the full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement, including any and all post-effective amendments, and to file such amendments thereto, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

     

    /s/ Ryan M. Confer

    Ryan M. Confer

     

    President, Chief Executive Officer, Chief Financial Officer and Director

    (Principal Executive Officer and Principal Financial and Accounting Officer)

     

    June 26, 2026

     

     

     

    /s/ Brent M. Longnecker

    Brent M. Longnecker

    Director

    June 26, 2026
         

    /s/ Jose Antonio Moreno Toscano

    Jose Antonio Moreno Toscano

    Chairman of the Board June 26, 2026
         

    /s/ Will R. Wilson, Jr.

    Will R. Wilson, Jr.

    Director June 26, 2026

     

     

    II-3
    Get the next $GNPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Longnecker Brent M

    4 - Genprex, Inc. (0001595248) (Issuer)

    4/15/26 6:50:54 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 7,168 shares, decreasing direct ownership by 25% to 21,692 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/27/26 6:34:18 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 9,330 shares, decreasing direct ownership by 20% to 36,331 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/27/26 6:33:20 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

    Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

    6/22/26 9:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex to Participate at BIO International Convention 2026

    The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The WorldAUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2026 International Convention taking place June 22-25, 2026 in San Diego, California. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Li

    6/17/26 9:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

    Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas, May 26, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract details positive clinical data from studies of predicti

    5/26/26 8:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    SEC Filings

    View All

    SEC Form S-8 filed by Genprex Inc.

    S-8 - Genprex, Inc. (0001595248) (Filer)

    6/26/26 4:46:21 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    6/22/26 9:02:23 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    6/18/26 4:01:04 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    National Securities initiated coverage on Genprex with a new price target

    National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

    1/26/21 7:48:53 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

    Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

    5/13/24 8:31:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

    Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

    8/22/23 7:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Genprex Inc.

    SC 13G/A - Genprex, Inc. (0001595248) (Subject)

    10/24/24 12:23:37 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/22/24 12:01:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/3/24 10:09:50 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care